Equities Analysts Offer Predictions for TSE:FRX Q1 Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX) – Stock analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Fennec Pharmaceuticals in a report issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of ($0.03) for the quarter, down from their prior forecast of $0.10. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q2 2026 earnings at $0.07 EPS, FY2026 earnings at $0.43 EPS, Q1 2027 earnings at $0.24 EPS and Q2 2027 earnings at $0.31 EPS.

Separately, B. Riley Financial raised Fennec Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Strong Buy”.

Fennec Pharmaceuticals Price Performance

FRX opened at C$8.33 on Wednesday. Fennec Pharmaceuticals has a fifty-two week low of C$7.02 and a fifty-two week high of C$13.83. The firm has a market capitalization of C$284.58 million, a PE ratio of -23.80 and a beta of 3.01. The company’s 50-day moving average is C$10.53 and its 200 day moving average is C$11.11.

Insiders Place Their Bets

In other news, Director Rostislav Christov Raykov bought 15,598 shares of the stock in a transaction dated Monday, February 2nd. The stock was bought at an average price of C$3.37 per share, for a total transaction of C$52,565.26. Following the completion of the acquisition, the director directly owned 2,719,643 shares in the company, valued at approximately C$9,165,196.91. This trade represents a 0.58% increase in their position. Company insiders own 16.20% of the company’s stock.

Fennec Pharmaceuticals News Roundup

Here are the key news stories impacting Fennec Pharmaceuticals this week:

• Positive Sentiment: Company reported record PEDMARK sales in 2025 and described building clinical and commercial momentum, which supports revenue growth expectations and longer-term upside for the stock. Fennec Posts Record PEDMARK Sales in 2025
• Positive Sentiment: HC Wainwright issued a bullish FY2027 outlook (firm-level FY2027 EPS of $1.33 and multiple positive quarterly forecasts for 2027), implying substantial earnings expansion potential beyond 2026. This supports a constructive long-term thesis if execution and sales momentum continue. HC Wainwright Estimates (MarketBeat)
• Negative Sentiment: HC Wainwright cut several near-term estimates — notably Q1 & Q2 2026 and lowered FY2026 EPS from $0.88 to $0.43 — signaling weaker near-term profitability expectations; those revisions typically pressure the stock as they reduce near-term earnings visibility. HC Wainwright Cuts (MarketBeat)
• Negative Sentiment: Company disclosed inducement option grants (377,500 ISOs) approved by the compensation committee, which can lead to potential dilution and is often viewed as a mild headwind to share value until exercised or offset. Fennec Announces Inducement Grants

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.